Pergolide Treatment of Cognitive Deficits Associated with Schizotypal Personality Disorder: Continued Evidence of the Importance of the Dopamine System in the Schizophrenia Spectrum Authors: Margaret M McClure, Philip D Harvey, Marianne Goodman, Joseph Triebwasser, Antonia New, Harold W Koenigsberg, Larry J Sprung, Janine D Flory, Larry J Siever Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 01/02/2010; Cognitive deficits observed in schizophrenia are also frequently found in individuals with other schizophrenia spectrum disorders, such as schizotypal personality disorder (SPD). Dopamine appears to be a particularly important modulator of cognitive processes such as those impaired in schizophrenia spectrum disorders. In a double-blind, placebo-controlled clinical trial, we administered pergolide, a dopamine agonist targeting D(1) and D(2) receptors, to 25 participants with SPD and assessed the effect of pergolide treatment, as compared with placebo, on neuropsychological performance. We found that the pergolide group showed improvements in visual- spatial working memory, executive functioning, and verbal learning and memory. These results suggest that dopamine agonists may provide benefit for the cognitive abnormalities of schizophrenia spectrum disorders. Neuropsychopharmacology advance online publication, 3 February 2010;
An American atheist same-sex sexual predator is attempting to disrupt this thread ..
Ignore him ..
"Dopamine agonists may provide benefit"
Pergolide Treatment of Cognitive Deficits Associated with Schizotypal Personality Disorder: Continued Evidence of the Importance of the Dopamine System in the Schizophrenia Spectrum Authors: Margaret M McClure, Philip D Harvey, Marianne Goodman, Joseph Triebwasser, Antonia New, Harold W Koenigsberg, Larry J Sprung, Janine D Flory, Larry J Siever Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 01/02/2010; Cognitive deficits observed in schizophrenia are also frequently found in individuals with other schizophrenia spectrum disorders, such as schizotypal personality disorder (SPD). Dopamine appears to be a particularly important modulator of cognitive processes such as those impaired in schizophrenia spectrum disorders. In a double-blind, placebo-controlled clinical trial, we administered pergolide, a dopamine agonist targeting D(1) and D(2) receptors, to 25 participants with SPD and assessed the effect of pergolide treatment, as compared with placebo, on neuropsychological performance. We found that the pergolide group showed improvements in visual- spatial working memory, executive functioning, and verbal learning and memory. These results suggest that dopamine agonists may provide benefit for the cognitive abnormalities of schizophrenia spectrum disorders. Neuropsychopharmacology advance online publication, 3 February 2010;
An American atheist same-sex sexual predator is attempting to disrupt this thread ..
Ignore him ..
"Dopamine agonists may provide benefit"
Pergolide Treatment of Cognitive Deficits Associated with Schizotypal Personality Disorder: Continued Evidence of the Importance of the Dopamine System in the Schizophrenia Spectrum Authors: Margaret M McClure, Philip D Harvey, Marianne Goodman, Joseph Triebwasser, Antonia New, Harold W Koenigsberg, Larry J Sprung, Janine D Flory, Larry J Siever Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 01/02/2010; Cognitive deficits observed in schizophrenia are also frequently found in individuals with other schizophrenia spectrum disorders, such as schizotypal personality disorder (SPD). Dopamine appears to be a particularly important modulator of cognitive processes such as those impaired in schizophrenia spectrum disorders. In a double-blind, placebo-controlled clinical trial, we administered pergolide, a dopamine agonist targeting D(1) and D(2) receptors, to 25 participants with SPD and assessed the effect of pergolide treatment, as compared with placebo, on neuropsychological performance. We found that the pergolide group showed improvements in visual- spatial working memory, executive functioning, and verbal learning and memory. These results suggest that dopamine agonists may provide benefit for the cognitive abnormalities of schizophrenia spectrum disorders. Neuropsychopharmacology advance online publication, 3 February 2010;
An American atheist same-sex sexual predator is attempting to disrupt this thread ..
Ignore him ..
"Dopamine agonists may provide benefit"
Pergolide Treatment of Cognitive Deficits Associated with Schizotypal Personality Disorder: Continued Evidence of the Importance of the Dopamine System in the Schizophrenia Spectrum Authors: Margaret M McClure, Philip D Harvey, Marianne Goodman, Joseph Triebwasser, Antonia New, Harold W Koenigsberg, Larry J Sprung, Janine D Flory, Larry J Siever Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 01/02/2010; Cognitive deficits observed in schizophrenia are also frequently found in individuals with other schizophrenia spectrum disorders, such as schizotypal personality disorder (SPD). Dopamine appears to be a particularly important modulator of cognitive processes such as those impaired in schizophrenia spectrum disorders. In a double-blind, placebo-controlled clinical trial, we administered pergolide, a dopamine agonist targeting D(1) and D(2) receptors, to 25 participants with SPD and assessed the effect of pergolide treatment, as compared with placebo, on neuropsychological performance. We found that the pergolide group showed improvements in visual- spatial working memory, executive functioning, and verbal learning and memory. These results suggest that dopamine agonists may provide benefit for the cognitive abnormalities of schizophrenia spectrum disorders. Neuropsychopharmacology advance online publication, 3 February 2010;
|
